Flucelvax Tetra Suspension injectable

Pays: Suisse

Langue: français

Source: Swissmedic (Swiss Agency for Therapeutic Products)

Ingrédients actifs:

haemagglutininum influenzae A (H3N2) (Virus Stamm A/Kansas/14/2017 (H3N2)-like: derived from A/Indiana/08/2018), haemagglutininum influenzae A (H1N1) (Virus Stamm A/Brisbane/02/2018 (H1N1)-like: derived from A/Idaho/07/2018), haemagglutininum influenzae B (Virus Stamm B/Colorado/06/2017-like: reassortant from B/Iowa/06/2017 (Victoria lineage))

Disponible depuis:

Medius AG

Code ATC:

J07BB02

DCI (Dénomination commune internationale):

haemagglutininum influenzae A (H3N2) (Virus Stamm A/Kansas/14/2017 (H3N2)-like: derived from A/Indiana/08/2018), haemagglutininum influenzae A (H1N1) (Virus Stamm A/Brisbane/02/2018 (H1N1)-like: derived from A/Idaho/07/2018), haemagglutininum influenzae B (Virus Stamm B/Colorado/06/2017-like: reassortant from B/Iowa/06/2017 (Victoria lineage))

forme pharmaceutique:

Suspension injectable

Composition:

haemagglutininum influenzae A (H3N2) (Virus Stamm A/Kansas/14/2017 (H3N2)-like: derived from A/Indiana/08/2018) 15 µg, haemagglutininum influenzae A (H1N1) (Virus Stamm A/Brisbane/02/2018 (H1N1)-like: derived from A/Idaho/07/2018) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Colorado/06/2017-like: reassortant from B/Iowa/06/2017 (Victoria lineage)) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Phuket/3073/2013-like: reassortant from B/Singapore/INFTT-16-0610/2016 (Yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, magnesii chloridum hexahydricum, natrii dihydrogenophosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.7 mg, kalium 0.1 mg, residui: polysorbatum 80, cetrimidum, propiolactonum.

classe:

B

Groupe thérapeutique:

Les vaccins

Domaine thérapeutique:

aktive Immunisierung gegen Influenza , ab 9 Jahren

Statut de autorisation:

zugelassen

Date de l'autorisation:

2021-05-04